NCT05838781Completed
DeteCtiON and Stroke PreventIon by MoDEl ScRreenING for Atrial Fibrillation
Source: ClinicalTrials.gov · Last updated 22 May 2024
Brief summary (registry, in English)
Atrial fibrillation (AF) is the most common clinical arrhythmia and the prevalence increases with age. AF increases the risk of ischaemic stroke fivefold and accounts for almost one-third of all strokes. As AF is often asymptomatic there are many undetected cases. It is important to find patients with AF and additional risk factors for stroke in order to initiate oral anticoagulation treatment, which can reduce the risk of an ischaemic stroke by 60-70%. Screening is recommended in European guidelines, however the most suitable population and the most suitable device for AF detection remain to be defined. The main objective of this study is to test the hypothesis that AF screening with 14-days continuous ECG monitoring in high-risk individuals identified with a risk prediction model is more effective than routine care in identifying patients with undetected AF. Effectively detecting AF among patients with risk factors for ischaemic stroke has the potential to decrease mortality and morbidity, stroke burden and costs for the society as a whole.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 2112 (actual)
- First submitted
- 20 Apr 2023
- Start date
- 4 Dec 2023
- Primary completion date
- 16 May 2024
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Stroke, Atrial fibrillation
- NCT number
- NCT05838781
What you commit to
- Study type: Interventional
- Participants enrolled: 2112
- From 4 Dec 2023 to the primary completion date, 16 May 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Dementia
- Other indication for OAC treatment (such as VTE, mechanical heart valve replacement, VTE prophylaxis post surgery, mitral stenosis, left side intracardial thrombus)
Other
- Known atrial fibrillation
- Death
- No longer resident in Region Halland
- Pacemaker, implantable cardioverter defibrillator or insertable monitor
Who the study is looking for
- Alive residents in the Halland region aged 65 or older without a recorded diagnosis of AF
Age in the registry: 65 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Karolinska Institutet Danderyd University Hospital Coordinator of this site? Confirm its status | Stockholm | Sweden | Unknown status |
| Halland Hospital Varberg Coordinator of this site? Confirm its status | Varberg | Sweden | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.